louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01373775: Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department Siriraj Hospital
Official title: Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department in Siriraj Hospital: The One Year Period.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Congestive Heart Failure
Renal Insufficiency
Keywords: Heart failure
Revisit
Emergency room
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2011-06-15
Enrollment: 533
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Medical records of 533 patients,who visited the emergency department with the diagnosis of HF (ICD-10 I500, I501 and I509) in the period from 1st Jan 2008 to 31st Dec 2008, were reviewed.

Brief summary: To identify the risk factors of the revisit of the adult HF patients in emergency department.

Detailed description: Because heart failure (HF) is the leading cause of hospitalization and readmission in many hospitals worldwide.

Identifying the risk factors of these HF patients in emergency department is the important reason for the proper management of the HF patients in the future. And can reduce number of hospitalization and readmission in our hospital.

Eligibility criteria: Inclusion Criteria:

* Patients age from 18 years old
* Patients who were diagnosed HF by the Framingham's criteria10
* Patients who were discharged home from emergency department

Exclusion Criteria:

* Patients age less than 18 years old
* Patients who not met Framingham's criteria, needed hospital admission, were referred to other hospital, and death

Primary outcomes:
measure: Number of HF patients who were revisited emergency department before the appointment date.
timeFrame: 1 year
Secondary outcomes:
measure: Characteristics of the patients in revisit group
timeFrame: 1 year
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Emergency department, Siriraj hospital
Study officials:
affiliation: Department of Anesthesiology
name: Phuriphong Songarj, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06833775: Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI
Official title: Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Esophageal Cancer
Neoadjuvant Therapy
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2025-02-19
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients were diagnosed with esophageal cancer by pathology at Zhengzhou University Affiliated Cancer Hospital from January 1, 2017 to December 31, 2024. Based on pre-treatment examinations such as endoscopic ultrasound, CT, MRI, and multidisciplinary consultation opinions, these patients underwent radical esophagectomy after receiving different kinds of neoadjuvant therapy.

Brief summary: This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as well as clinical indicators collected before and after neoadjuvant treatment.


Eligibility criteria: Inclusion Criteria:

1. Consecutive patients with histopathological diagnosis of esophageal cancer.
2. Patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy.
3. All patients underwent CT and multimodal MRI examinations before and after neoadjuvant therapy.
4. The preoperative clinical data and postoperative pathological data are complete.

Exclusion Criteria:

1. Patients with other primary malignant tumors or previous anti-tumor treatment.
2. CT and MRI images with poor quality.

Primary outcomes:
measure: CT and multimodal MRI in prediction of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer
timeFrame: March 2025 - January 2030
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00591175: A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers
Official title: A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Smoking Cessation
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: NYU College of Dentistry
First posted: 2008-01-11
Enrollment: 1072
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Smokers who are also patients at the NYU College of Dentistry

Brief summary: The goal of this study is to see if giving patients information about how smoking affects oral health will help them quit smoking. What we learn from this study will help researchers find new ways to help smokers.


Eligibility criteria: Inclusion Criteria:

* Patient seeking routine dental care at NYU College of Dentistry and meets medical clearance for routine care
* Active smokers (active smoking as self-reported regular use of at least 10 cigarettes per day)
* Able to provide a telephone number or collateral contact information where they can be reached over the subsequent 12 months
* Fluent in English or Spanish

Exclusion Criteria:

* History of mouth or throat cancer

Primary outcomes:
measure: efficacy of varied smoking cessation interventions
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Jamie Ostroff, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Holliday R, Hong B, McColl E, Livingstone-Banks J, Preshaw PM. Interventions for tobacco cessation delivered by dental professionals. Cochrane Database Syst Rev. 2021 Feb 19;2(2):CD005084. doi: 10.1002/14651858.CD005084.pub4.
Clinical trial NCT00390975: Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
Official title: An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Gastroparesis
Diabetes
Keywords: Tegaserod
diabetes
diabetic gastroparesis
gastric emptying
gastric retention
electrogastrography
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-10-23
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.


Eligibility criteria: Inclusion Criteria:

* Females and males 18 to 75 years of age
* History of type I or type II diabetes mellitus for more than 3 years
* History of upper gastrointestinal symptoms consistent with diabetic gastroparesis
* Hemoglobin A1c \< 9.5%
* Delayed gastric emptying

Exclusion Criteria:

* Abnormal endoscopy finding that can explain the presence of gastroparesis symptoms
* Medical conditions affecting gastric emptying
* A clinically significant medical condition that would interfere with the patient completing the trial
* Clinically significant abnormal creatinine level
* Known allergies to the same class of drug and/or allergies to eggs
* Severe obesity

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET)
Secondary outcomes:
measure: Change from baseline in patients treated with tegaserod relative to: The proportion of patients that normalize gastric emptying
measure: Symptoms of diabetic gastroparesis including postprandial fullness, early satiety, bloating, nausea and vomiting, and abdominal discomfort
measure: Volume and symptomatic response to a gastric satiety drink test (GSDT)
measure: Electrogastrography (EGG)
measure: The safety and tolerability of tegaserod
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: The University of Kansas Medical Center
state: Kansas
city: Louisville
country: United States
facility: The University of Louisville
state: Kentucky
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
Study officials:
affiliation: NPC
name: Novartis Pharmaceutical Corporation
role: STUDY_CHAIR
References:
Clinical trial NCT01286675: Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
Official title: A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Multiple Myeloma
Keywords: ASCT
G-CSF
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
First posted: 2011-01-31
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Eltrombopag may improve the cell collection available for Autologous Stem Cell Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and reduce the number of times blood needs to be collected. This study will also determine the highest dose of Eltrombopag that can be used without causing serious side effects.

Detailed description: Subjects will receive standard treatment for autologous stem cell transplant. Subjects will be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag. Subjects will receive oral Eltrombopag on days 2-15 of treatment.

Eligibility criteria: Inclusion Criteria:

* Multiple myeloma
* Stable or responsive disease after at least 2 cycles of conventional chemotherapy
* Slated to undergo autologous peripheral blood stem cell transplant
* Normal organ and marrow function

Exclusion Criteria:

* Myocardial infarction within 6 months of treatment
* Receiving other study agents
* Pregnant or breastfeeding
* Uncontrolled intercurrent illness
* Evidence of active or recent history of thromboembolic disease
* Previous history of primary platelet disorder or bleeding disorder
* History of a different malignancy unless disease free for at least 5 years

Primary outcomes:
measure: Evaluate the median fold increase in the number of CD34+ cells/kg mobilized at each dose level.
timeFrame: 1 year
measure: Evaluate the number of apheresis procedures required to obtain at least 2 x 10^6 CD34+ cells/kg at each dose level
timeFrame: 1 year
measure: Determine the maximum tolerated dose of eltrombopag with granulocyte colony-stimulating factor.
timeFrame: 1 year
Secondary outcomes:
measure: Evaluate the median fold increase in platelet counts at each of the dose levels
timeFrame: 1 year
measure: Evaluate the median fold increase in hematopoietic colony forming capacity of CD34+ cells at each dose level
timeFrame: 1 year
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Nancy Berliner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02238275: Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension
Official title: Post-Marketing Surveillance Study Micardis® Plus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-12
Enrollment: 8135
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatients with hypertension

Brief summary: Study to evaluate efficacy and tolerability of Micardis® plus under usual daily-practice prescribing-conditions


Eligibility criteria: Inclusion Criteria:

* Adult (Age \>= 18 years) males and females for whom a medical antihypertensive therapy is indicated

Exclusion Criteria:

* Age \< 18 years

Primary outcomes:
measure: Change from baseline in morning blood pressure
timeFrame: Baseline, after 6 weeks
measure: Change from baseline in classification of blood pressure
timeFrame: Baseline, after 6 weeks
Secondary outcomes:
measure: Number of patients with adverse drug reactions
timeFrame: up to 6 weeks
measure: Assessment of efficacy by investigator on 5-point scale
timeFrame: after 6 weeks
measure: Assessment of tolerability by investigator on a 5-point scale
timeFrame: after 6 weeks
measure: Change from baseline in heart rate
timeFrame: Baseline, after 6 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06849375: Corneal Endothelial Assessment After Posterior Chamber Phakic Intraocular Lens Implantation
Official title: Corneal Endothelial Assessment After Posterior Chamber Phakic Intraocular Lens Implantation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Corneal Endothelial Cells
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2025-02-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: our primary aim of the work to assess the effect of phakic IOL implantation on corneal endothelium. we also used the specular microscope to assess the corneal endothelium


Eligibility criteria: Inclusion Criteria:

* Our inclusion criteria include: adults 18-35 years of age, myopia ˃ 6 D , anterior chamber depth (ACD) 2.85 mm or greater , an endothelial cell count of ≥ 2000 cells/mm2 and stable refractive history within 0.5 diopter for 1 year.

Exclusion Criteria:

* anterior chamber depth from endothelium \< 2.85 mm, previous or current systemic or eye disease , surgery or trauma, pregnancy and nursing.

Primary outcomes:
measure: corneal endothelial cells assessment
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag University Hospital
Study officials:
References:
citation: Reinstein DZ, MacGregor C, Archer TJ, Gupta R, Potter JG. A review of posterior chamber phakic intraocular lenses. Curr Opin Ophthalmol. 2024 Mar 1;35(2):138-146. doi: 10.1097/ICU.0000000000001018. Epub 2023 Dec 6.
citation: Taneri S, Dick HB. Initial clinical outcomes of two different phakic posterior chamber IOLs for the correction of myopia and myopic astigmatism. Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1763-1772. doi: 10.1007/s00417-021-05465-w. Epub 2021 Nov 6.
citation: Chaurasia S, Vanathi M. Specular microscopy in clinical practice. Indian J Ophthalmol. 2021 Mar;69(3):517-524. doi: 10.4103/ijo.IJO_574_20.
citation: Sridhar MS. Anatomy of cornea and ocular surface. Indian J Ophthalmol. 2018 Feb;66(2):190-194. doi: 10.4103/ijo.IJO_646_17.
citation: DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011 Mar;37(3):588-98. doi: 10.1016/j.jcrs.2010.12.037.
Clinical trial NCT00088075: Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
Official title: A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Schizophrenia
Keywords: Schizophrenia
Risperidone
Adolescents
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor class: INDUSTRY
First posted: 2004-07-21
Enrollment: 160
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A clinical study to evaluate the efficacy, safety and tolerability of two dose ranges of risperidone (1 to 3 mg/day, and 4 to 6 mg/day) versus placebo (an inactive substance like a sugar pill) in adolescents (aged 13 to 17 years) with schizophrenia (i.e. abnormal behavior and thoughts). The study duration is about 6 to 7 weeks.

Detailed description: Subjects will be aged 13 to 17 years with a diagnosis of schizophrenia. On enrollment, subjects will be assigned to receive 1 of 3 treatments (oral placebo tablets, oral risperidone tablets 1 to 3 mg, or oral risperidone tablets 4 to 6 mg), which will be administered daily for 6 weeks. Study medication will be increased to within the target dosage range during the first 7 days and then further increased until the maximum tolerated dose is achieved by day 14. The maximum tolerated dose will be maintained for the last 4 weeks of the study, unless dose adjustments are agreed with the Sponsor. Risperidone (1 to 3 mg or 4 to 6 mg) or placebo given orally as 0.5, 1, 2, 3, or 4 ,g tablets (or matching placebo) each day for 6 weeks.

Eligibility criteria: Inclusion Criteria:

* A responsible person must be available to accompany the subject to the site at each visit
* patient must meet the DSM-IV criteria for schizophrenia

Exclusion Criteria:

* Patients with mild, moderate or severe mental retardation
* patients with a known or suspected history of substance dependence
* subjects weighing \<35kg
* subjects who cannot swallow oral tablets

Primary outcomes:
measure: Change in total PANSS (Positive and Negative Syndrome Scale for Schizophrenia) from baseline to the 6-week endpoint
Secondary outcomes:
measure: Change from baseline in PANSS subscale scores and Clinical Global Impression (CGI-S and CGI-I) scores, number of subjects achieving a clinical response (at least 20% improvement in total PANSS), safety and tolerability.
Other outcomes:
Locations:
Study officials:
affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
role: STUDY_DIRECTOR
References:
citation: Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009 Dec;19(6):611-21. doi: 10.1089/cap.2008.0144.
Clinical trial NCT04810975: Strength Training Effects on Musculoskeletal Health
Official title: Strength Training Effects on Musculoskeletal Health, Melatonin, Rest-activity Rhythms and Quality of Life: Muscle:Time Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Musculoskeletal Diseases
Lead sponsor: Duquesne University
Sponsor class: OTHER
Collaborators: name: Jaquish Biomedical
First posted: 2021-03-23
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective here is to assess the efficacy of variable resistance muscle training on bone, sleep parameters and quality of life in healthy populations of men and women age 30 or older.


Eligibility criteria: Inclusion Criteria:

* 30 years or older (males or females)
* Baseline strength (e.g., can lift an office chair with no problems)
* Be willing to participate in a 6-month RCT
* Be willing to conduct daily muscle training exercises
* Be willing to maintain a food diary
* Be willing to consume \~2.2g/kg body weight daily
* Be willing to submit specimens and conduct tests 3 times over 6 months (0, 3 and 6 months)

Exclusion Criteria:

* those who consume vegan or vegetarian diets
* people with conditions like hypertension and uncontrolled non-medicated blood pressure; cardiovascular disease/heart failure (e.g., arrhythmias, unstable angina, congestive heart failure)
* COPD
* drugs that may increase fall risk or make dizzy (e.g., antidepressants, anti-seizure drugs)
* muscle disease (e.g., myasthenia gravis, myopathy, myositis)
* active hernia
* pregnancy
* muscle atrophy (e.g., Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), ALS)
* neuro degenerative disease
* limited mobility
* those who consume proteins supplements.
* Individuals who have implanted pacemakers or defibrillators
* People who suffer from: Marfan syndrome, migraine, hyperparathyroidism, metastatic bone disease, multiple myeloma
* chronic steroid use
* individuals with restrictions to movement and exercise

Primary outcomes:
measure: Lean Body Mass
timeFrame: 0-6 months
measure: Body Circumference
timeFrame: 0-6 months
measure: Functional test 1 to assess musculoskeletal strength
timeFrame: 0-6 months
measure: Functional test 2 to assess musculoskeletal strength
timeFrame: 0-6 months
measure: Bone marker activity-bone resorption
timeFrame: 0-6 months
measure: Bone marker activity-bone formation
timeFrame: 0-6 months
measure: Ratio of bone resorption to bone formation
timeFrame: 0-6 months
measure: Hormone levels-Testosterone
timeFrame: 0-6 months
measure: Hormone levels-Cortisol
timeFrame: 0-6 months
measure: Inflammatory Marker
timeFrame: 0-6 months
measure: Rest-activity rhythms
timeFrame: 0-6 months
measure: Melatonin
timeFrame: 0-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Duquesne University
state: Pennsylvania
Study officials:
affiliation: Duquesne University
name: Paula Witt-Enderby, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: